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Abstract 
 
Cancer is a complex class of diseases that are characterized by out-of-control cell growth in the 
human body. They cause harm to the body when they form into tumours and are responsible on a 
global scale for millions of deaths annually. Breast cancer is one of the leading causes of death in 
women specifically. It has been linked to factors that are associated with obesity such as adipose 
tissue, high insulin, and many other factors. The ketogenic diet is a low carb, moderate protein, 
and high fat diet that helps to reduce adipose tissue markers associated with obesity and cancer. 
Fat metabolism and ketone production may also help to fight cancer cell growth by starving 
tumours of glucose. More specifically, physiological levels of ketones and glucose seen on a 
ketogenic diet may also shift cancer cells to a dysfunctional oxidative phosphorylation within the 
mitochondria while raising levels of cell cycle inhibitors.  
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1.0 - Review of Literature: 
The cell cycle is a tightly regulated process that can be disrupted by external factors. 
Factors that disrupt the cell cycle and lead to cancer are higher in the obese population. Work 
done in our lab (Theriau and Connor, 2017) has shown that fat tissue from lean rats is able to 
slow down cancer cell growth, compared to obese adipose tissue. Knowing that we can slow 
down or prevent cancer cell growth by reducing excess adipose tissue and thus overall body fat is 
extremely helpful in the future direction of cancer research. A prevention model should be 
carefully examined and given much thought. In this regard, the ketogenic diet has consistently 
shown to be the most effective method of losing body fat (relative to other diets) and has been 
shown to reduce markers of cancer cell growth (Jansen and Walach, 2016). The benefits are two-
fold: reducing adipose tissue and markers associated with cancer cell growth, as well as reducing 
glucose and insulin, known growth promoters of cancer cells. Studies done on mice and human 
tumours show a decrease in tumour size and glucose uptake (Veech, 2004). Thus, research into 
whether KD can elicit beneficial effects for obese cancer patients represents a novel direction for 
therapy/prevention.  
 
1.1 - Mammalian Cell Cycle: 
 
The mammalian cell cycle is a process by which cells divide, replicates their DNA and 
are divided into the two identical daughter cells. This is a tightly regulated process containing 
specific checkpoints to ensure accurate replication. The ability of cells to duplicate is dependent 
on Cyclin-Dependent Kinases (CDK) and Cyclins. The interaction between the CDKs 
(Serine/Threonine kinases) and their binding partners is one of the important factors that 
determines cell cycle progression and regulation of the transition steps (Figure 1). The cell cycle 
is split into four phases termed the gap 1 (G1), DNA replication (S), and gap 2 (G2) phases.  
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Progression through the mammalian cell cycle is dependent on factors that tightly regulate these 
phases. Prior to transition into S-phase the cell checks whether energy status is sufficient to 
support division while in G2 (Norbury et al. 1992). The cell determines if DNA damage or 
replication errors exist, and if they cannot be fixed, the cell will proceed to apoptosis (Figure 1). 
A biochemically distinct quiescent state (G0) can occur where the cell remains inactive until cell 
division replication is triggered by an external signal (Caldon et al. 2005).   
 
 
 
 
Figure 1: Control of cell-cycle progression from G1 into S phase. The cell decides whether it 
will commit during late G1/early S phase. 
Adapted from Bertoli et al. 2013. Nature Reviews: Molecular Cell Biology. 
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1.1.1– Regulation of the Cell Cycle: 
 
Transition between phases of the cell cycle is highly dependent on CDKs and Cyclins. 
The transitions from G1 to S phase and G2 to M phase are regulated by changes in levels of 
Cyclins and other post-translational modifiers (kinases and phosphatases). CDKs and Cyclins 
can be thought of as the engine of the cell cycle that progress the cell through each phase. While 
CDK proteins tend to stay at fairly constant levels throughout the cell cycle, as the name 
suggests Cyclins undergo temporal fluctuations in protein levels to regulate progression through 
the cell cycle. Cyclins are upregulated by transcription factors, which are increased by signaling 
pathways that are normally activated externally. Regulation of phase transitions depends on 
specific Cyclin-CDK complexes that target intermediary targets. During G1, the predominant 
Cyclin–CDK complexes are Cyclin D–CDK4/6 and Cyclin E–CDK2. During S phase Cyclin A–
CDK2 is activated while Cyclin A–CDK1 and Cyclin B–CDK1 are turned on during G2 and 
mitosis (Caldon et al. 2005). Cyclins are generally up-regulated at the transcriptional level, 
which ultimately increases protein expression. Conversely, the reductions in protein levels are 
regulated by changing their degradation through ubiquitin mediated proteolysis (Sherr et al. 
1999). My thesis will primarily focus on the transition from G1 to S-phase in order to slow 
cancer progression via regulation of these Cyclin-CDK complexes as deregulation of G1 is 
evident in the majority of cancers (Tenga and Lazar, 2013). 
The cell responds to growth-factor dependent signals during the early G1 phase and mis-
activation of CDK-Cyclin complexes can lead to growth in cancer cells. Specifically, the Cyclin 
E-CDK2 complex represents the checkpoint in the G1/S transition, and entry into the S phase 
(Koff et al. 1992). As an indication of its importance, Cyclin E is overexpressed in many breast 
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cancers and correlates with poor prognosis. Loss of Cyclin E-CDK2 regulation plays a role in 
cancer progression (Gladden et al. 2003).  
There are two families of Cyclin-dependent kinase inhibitors known as the INK4 
(inhibitors of CDK4) and KIP (kinase inhibitory protein) families. As their name suggests, they 
have the ability to inhibit the cell cycle during the G1/S transition by constraining the activity of 
specific CDKs. The inhibitor of CDK4 (INK4) proteins p16INK4a, p15INK4b, p18INK4c, and 
p19INK4d only bind to CDK4 and CDK6, and no other Cyclin/CDKs. During the G1 phase the 
kinase inhibitor proteins (KIP) p21 (WAF1/Cip1), p27 (Kip1), and p57 (Kip2) inactivate CDK2 
complexes by binding to both Cyclin and CDK subunits, thereby preventing kinase activity. One 
of the key inhibitors of the G1/S transition is p27Kip1, which antagonizes the activity of Cyclin E-
CDK2 and Cyclin A-CDK2, preventing premature passage through the G1/S transition (Sherr 
and Roberts, 1999). p27Kip1 impairs cell proliferation in both proliferative and quiescent cells 
(Xu et al. 1999), plays a crucial role in the G1/S transition through its regulation and localization 
(Satyanarayana & Kaldis, 2009) and therefore is an important protein with regards to cell cycle 
regulation.  
 
1.1.2 - p27kip1: 
 
 p27kip1 is a protein that is critical in the control of cell differentiation and cell cycle arrest. 
The expression of p27 is low in late G1 and stays low through M-phase. Also, p27 is low in the 
majority of tumours, so much so that it is used as a predictor of patient prognosis (Massagué, 
2004, Yang et al. 1998). The protein expression is primarily regulated at a post-translational 
level during late G1, with targeted degradation of p27 occurring through the ubiquitin-
proteasome pathway. The importance of p27 in cell cycle regulation has been demonstrated by 
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p27 -/- mice which developed specific tumours spontaneously and were more susceptible to 
tumours in the presence of chemical carcinogens (Nakayama et al. 1996). Low levels of p27 
protein expression correlate to poor prognosis and cancer patient survival (Sgambato et al. 2000). 
p27 forms a tight inhibition complex with CDK2/Cyclin E, independent of p27 phosphorylation 
state (Xu et al. 1999). During late G1 most of the p27 in proliferating cells is bound to Cyclin 
D/CDK4-6 and this sequesters p27 from CDK2/Cyclin E, partially removing p27 constraint and 
allowing the build-up to G1/S transition. Essentially, there is competition between Cyclin D-
dependent kinases and CDK2/Cyclin E for Cip/Kip proteins like p27 (Vlach et al. 1997). 
CDK2/Cyclin E directly phosphorylates p27 on its threonine 187 (T187) residue. The 
phosphorylation of p27 by CDK2/Cyclin E results in Ub-mediated removal of p27 from the cell 
which allows cells to transition from G1 to S phase. This process occurs in two steps: p27 is an 
inhibitor of CDK2/Cyclin E, but that phosphorylation of p27 by CDK2/Cyclin E can inactivate 
p27 as an inhibitor to promote cell cycle progression. CDK inhibitors are regulated at a post 
translational level and therefore rely on external signals. The manner in which they are regulated 
by their environment is of tremendous importance when analyzing the cell cycle in the role of 
cancer. 
p27 is an important independent prognostic factor in breast cancer, characterized by its 
strong inhibitory activity toward Cyclin E/CDK2, which allows it to directly inhibit similar 
CDK-Cyclin complexes and arrest cells in G1 (Lloyd et al. 1999). Most studies done on 
prognostic significance of p27 expression in tumours have reported a decrease in p27 expression 
in more aggressive tumours (Steeg and Abrams 1997). One study that analyzed p27 expression 
in breast cancer (202 patients, <1cm in size) found nodal status and low p27 expression to be 
independent prognostic parameters in various methods of analyses (Tan et al. 1997). Women 
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whose breast cancer did not spread to any lymph nodes (node negative) and lower levels of 
nuclear p27 had an increase in cancer relapse risk. There was a staggering 10-fold increase in the 
risk of relapse when compared to women with increased levels of nuclear p27 expression 
(Chappuis et al. 2000). The most significant prognostic factor in p27 is that its protein levels are 
high in most cases of breast carcinomas, and correlated with levels of Cyclin D1 and estrogen 
receptor, which presents a predictor of survival as they are low in aggressive carcinomas (Chiarle 
et al. 2000). 
 
1.1.3 -  Regulation and degradation of p27kip1: 
 
p27 is regulated at the translational level in late G1, early S phase. (Medema et al. 2000). 
This regulated degradation of p27kip1 during G1 and S phase is critical to allowing cell division. 
While the degradation is moderate during the G1 phase, it is enhanced during the S phase. The 
ubiquitin-proteasome system responsible for degradation of proteins is part of that regulatory 
process (Caldon et al. 2006). During G1 and S phase, the degradation of p27 is regulated by two 
RING-finger E3 ubiquitin ligase-containing complexes (Kamura et al. 2004). These have 
differing subcellular locations and timing to target p27 for proteasomal degradation via 
ubiquitylation. The first is a complex with 2 subunits, known as the Kip ubiquitin-promoting 
complex (KPC). It functions in the cytoplasm during G1 and is made up of KPC1 and KPC2, 
along with two E2 enzymes Ubc4 and UbcH5A. These are responsible for the initial loss of p27 
that activates CDK2/Cyclin E in the nucleus to promote S phase entry. The KPC1 and KPC2 
complexes are largely responsible for the initial loss of p27, with the CDK2/Cyclin E being 
responsible for the remaining nuclear export and degradation of p27. This mechanism is 
dependent on phosphorylation of p27 on its Serine-10 (S10) residue, known as human kinase 
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interacting stathmin (hKIS), which is located within the nucleus. It binds to the C-terminal 
domain of p27kip1, phosphorylating S10 to promote its nuclear export to the cytoplasm (Ishida et 
al. 2000) (Figure 2B). p27 nuclear export is dependent on MAPK activation and is activated in 
mid-late G. hKIS is largely responsible for regulating cell cycle progression by phosphorylating 
p27 in response to mitogens. This has been demonstrated by expression of hKIS overcoming cell 
cycle arrest by p27kip1. It is further demonstrated by siRNA depletion of KIS, inhibiting S10 
phosphorylation, and promoting growth arrest. Implications of p27kip1 as the critical target for 
KIS p27–/– cells with treatment of KIS siRNA that leads to growth and progression to S phase 
similar to control treated cells. (Boehm et al. 2002). The second mechanism of p27 degradation 
is triggered upon phosphorylation of p27 on a threonine residue (T187) by the CDK2/Cyclin E 
complex. Contrary to KPC1, this occurs in the nucleus during late G1, allowing for the binding 
of the SFC E3 ubiquitin ligase through the F-box protein Skp2 (Hengst, 2004) (Figure 2A). 
Typically, phosphorylation of CDK-bound p27 is done by free and active CDK2/Cyclin E, as the 
p27-bound CDK2 is catalytically inactive due to p27-mediated remodeling of its catalytic cleft 
and thus removal of ATP (Pavletich, 1999). Besides degradation, phosphorylation of p27 also 
plays a role in subcellular localization of the protein. Three tyrosine residues (Y74, Y88, Y89) 
have been associated with proteolysis of p27. A group of Src proteins can phosphorylate these 
amino acid residues to reduce nuclear p27 by impairing p27 inhibition of CDK2, and thus 
facilitating CDK2/Cyclin E-dependent p27 degradation (Chu et al. 2007) (Figure 2C). 
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Figure 2: Post-transcriptional regulation of p27. Some of the pathways regulating the 
phosphorylation, localization, and degradation of p27 have been identified and are illustrated 
here. (A) Degradation by F-box protein Skp2. (B) Phosphorylation of S10 by KIS to promote 
nuclear export to the cytoplasm. (C) Src proteins phosphorylate Y88, Y89, and Y74 to facilitate 
degradation. 
Adapted from Hnit et al. 2012. Int. J. Biochem. Cell Biol. 
 
1.1.4 – p27kip1 and AMPK: 
 
p27 can also be regulated by the energy level of the cell. The ATP levels determine if the 
inhibition of CDK2/Cyclin E occurs. In lower ATP levels (<50 m) p27 acts as a CDK inhibitor, 
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but at higher levels of ATP (>1mM) it is more likely to act as a substrate (Sheaff et al. 1997). 
While p27 phosphorylation sites are typically reserved for degradation or delocalization, there is 
a site for stability within the cell. AMPK, which is activated by AMP and LKB1 during 
conditions where there is a decline in ATP:ADP ratios in the cell, functions as an intracellular 
energy sensor that regulates cell metabolism and proliferation. It can phosphorylate p27 on the 
T198 residue to increase stability of the Cyclin-dependent kinase (Figure 3). The 
phosphorylation of p27 is important in quiescent cells and early G1 as it inhibits CDK2/Cyclin E 
leading to cell cycle arrest. LKB1-AMPK pathway-dependent phosphorylation of p27 at T198 
stabilizes p27, allowing cells to survive metabolic stress from autophagy and growth factor 
withdrawal. The LKB1-AMPK pathway regulates p27 protein abundance and T198 
phosphorylation, with data suggesting that T198 phosphorylation promotes p27 stability under 
metabolic stress. Additional research has shown a statistical correlation between LKB1 and p27 
in human breast cancer cell lines, specifically MFC7 cells (Liang et al. 2007). 
 
Figure 3: AMPK phosphorylates p27 at T198 to promote stability and prevent nuclear import. 
Adapted from Hnit et al. 2012. Int. J. Biochem. Cell Biol. 
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1.1.5 - Deregulation of p27kip1 in Cancer: 
 
In quiescent cells, p27 protein levels decrease after stimulation with mitogens, with 
expression of p27 in cultured cells causing cell cycle arrest in G1 (Toyoshima and Hunter, 1994). 
Mitogenic signals can inactivate p27kip1 through many mechanisms including suppression of 
transcription, inhibition of nuclear accumulation and sequestration by active Cyclin/CDK 
complexes. When Cyclin E/CDK2 is unhindered it targets p27 for degradation, which removes 
the inhibitor protein (Giancotti, 2004). This process also requires the F-box protein Skp2, and 
overexpression of this E3 ligase leads to diminishment of p27 in carcinomas, brain tumours, and 
lymphomas (Blain et al. 2003). Most of the p27 expression is regulated by mitogenic and anti-
mitogenic signaling that works to affect its translation, stability, and localization. Two 
commonly mutated pathways in human cancer are Ras/Raf/Mek1 and PI3K/Akt (Figure 4). 
These pathways directly impact the activity and abundance of p27 (Blain et al. 2003). Studies 
have even shown that the abundance of p27 in tumours is correlated with ubiquitin-dependent 
proteolysis. Overexpression of PI3K or loss of Pten also directly increase Skp2 levels 
(Mamillapalli et al., 2001). Many studies have been done on the overexpression of Ras, Cyclin E, 
and activation of MAPK. The results show that it reduces p27 stability while increasing p27 
phosphorylation and degradation (Pruitt and Der, 2001). The mislocalization of p27 to the 
cytoplasm in breast cancer directly affects its activity (Baldassarre et al. 1999). Poor long-term 
survival in breast cancer has been directly correlated with cytoplasmic p27 (Liang et al. 2002).  
The inability of cytoplasmic p27 to inhibit downstream nuclear Cyclin-CDK targets prevents cell 
cycle arrest. Ras overexpression contributes to an increase in cytoplasmic p27. Cytoplasmic 
mislocalization of p27 can also occur from oncogenically activated Akt, which phosphorylates 
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p27 on its T157 residue (Liu et al. 2000). p27 can also be inactivated in human tumours through 
sequestration by Cyclin D-CDK4/6 (Baldassarre et al. 1999). The two previously mentioned 
pathways, Ras/Raf/Mek1 and PI3K/Akt, directly affect Cyclin D levels. This interaction between 
the two pathways and Cyclin D may impact p27 localization indirectly. Cyclin D1 is upregulated 
by MAPK activation, and its degradation is inhibited by Akt-dependent phosphorylation of 
GSK3-β. These mechanisms further increase the inhibition of p27 of downstream targets through 
ensuing sequestration (Pruitt and Der, 2001) (Figure 4). p27 is also phosphorylated by Akt on 
two of its threonine residues (T157 and T198). The PKB/Akt pathway is responsible for 
impairing nuclear import and the action of p27, which contributes to resistance to 
antiproliferative signals and breast cancer progression (Figure 4). Protein Kinase B (PKB/Akt) 
indirectly reduces p27kip1 by triggering a pathway that inhibits Forkhead family transcription 
factors and tumour suppressor tuberin (TSC2) (Liang and Slingerland, 2003). Studies on Akt 
have demonstrated that p27 phosphorylation by the oncogenically activated Akt/PKB prevents 
the capacity of p27 to localize in the nucleus. Since p27 is a direct inhibitor of CDK2 and cell 
cycle arrest, it provides an advantage to tumour growth and contributes to genome instability. 
Akt-phosphorylated p27 correlate with tumour aggressiveness the same way a decrease in p27 
expression would (Blain and Massagué). Activated Akt can play an important role in breast 
cancer. In normal breast tissue the majority of p27 is nuclear with activated Akt being 
undetectable. While in many tumours p27 expression is low, there are a significant portion of 
tumours that express “normal” or greater than normal levels of p27. However, multiple studies 
have found that in 40% of p27-positive breast carcinomas, cytoplasmic p27 occurs with 
correlated activated Akt (Viglietto et al. 2002). This highlights targeting Akt as a viable 
therapeutic avenue.  
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Figure 4: p27 is targeted by multiple oncogenic stimuli including the PI3K/Akt and Ras 
pathway. These all work to reduce the inhibitory effect caused by p27 on the cell cycle. 
Adapted from Blain et al. 2003. Cancer Cell. 
 
This notion of higher p27 levels and its negative impact has proven to be significant as a 
prognostic factor. Women with breast cancer and higher nuclear p27 expression in their tumours 
showed an increase in survival and longer relapse period relative to women with low nuclear p27 
expression in their tumours. In the same study (Gillett et al. 1999) 80% of patients with tumours 
high in p27 expression survived compared to only 50% of patients with tumours low in p27 
expression. p27 is clearly a strong predictor of tumour aggressiveness and survival in cancer 
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patients, specifically in breast carcinomas. Its regulation, and thus expression should be carefully 
looked at in order to maintain proper p27 function and prevent breast cancer progression.  
 
1.2 – Obesity: 
 
Obesity is important on a global scale. It has many public health implications, especially 
in North America. Obesity is defined as “a condition of abnormal or excessive fat accumulation 
in adipose tissue, to the extent that health is impaired” (Drewnowski, 1989). It is associated with 
premature death from cardiovascular diseases (CVD) including hypertension, stroke, and 
coronary heart disease. It is also associated with disability or premature death from type 2 
diabetes mellitus (T2DM), gall bladder disease, and cancer (colon, breast, endometrial, prostate). 
The classification of obesity is typically done with a person’s BMI (body mass index). This 
represents their weight as a distribution of their height, and the range of BMI is used to assign 
body class. While BMI is limited in its application and only a crude measure of body fat 
percentage, it is a fair and easily obtained estimate in obesity classes. It is calculated by the 
weight of an individual in kilograms divided by the square of their height in metres (kg/m2). By 
the current World Health Organisation (WHO) criteria, a BMI <18.5kg/m2 is considered 
underweight, 18.5–24.9 kg/m2 ideal weight and 25–29.9kg/m2 overweight or pre-obese. The 
obese category is sub-divided into obese class I (30–34.9kg/m2), obese class II (35–39.9kg/m2) 
and obese class III (≥40kg/m2; WHO, 2000). Having a BMI considered overweight or pre-obese 
is associated with a three to four-fold greater risk of morbidity in adults due to T2DM and CVDs 
than the average person (Van Itallie, 1995). 
Obesity rates are at an all-time high and have grown significantly in the past few decades. 
From 1995 to 2000, the number of obese adults worldwide grew from 200 to 300 million. This 
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number has tripled since 1975, and by 2016 more than 1.9 billion adults, 18 years and older, are 
overweight. Out of this large group, over 650 million adults are considered obese (WHO, 2016). 
Obesity appears to be a global issue and not just a first world problem, with 115 million people 
suffering from obesity-related illnesses in developing countries. All of this is accompanied with 
an increase in childhood obesity and issues stemming from younger generations (Ong et al. 
2000). As of 2015, over a third of the world’s population is considered overweight or obese. This 
number is projected to increase to 58% of the world’s population. Specifically, in the USA the 
projections are over 85% of adults being overweight or obese by 2030 (Hruby and Hu, 2015). 
What is most important to note is that gender also plays a large role in obesity. Women are more 
affected by extreme obesity than men (classes 2–3, BMI ≥35 kg/m2), and this is independent of 
age and race/ethnicity (Ogden et al. 2014). Of the more recent numbers claiming that 1.5 billion 
adults are overweight, nearly 300 million women are considered clinically obese. Obesity in 
women can lead to polycystic ovarian syndrome (PCOS), insulin resistance, and breast cancer 
(Templeton, 2014). Obesity prevalence in women in Canada increase as age increases, which 
presents further concern for cancer risk. Obesity might be contributing to the earlier onset of 
cancers. By the year 2000, obesity in Canada was responsible for $2.0 billion in direct health 
care expenditures (Brian and Walsh, 2004). 
 
1.2.1 – Carbohydrate Intake & Obesity: 
 
In the United States alone, consumers annually spend more than $30 billion dollars on 
weight loss products and services (Serdula et al., 1999) along with $750 billion dollars on 
pharmaceuticals. While high levels of physical activity as a weight loss intervention are not 
always implemented and pursued with consistency in the North American lifestyle, drugs have 
    15 
often been considered as a substitute treatment plan. These drugs can often times cause harmful 
side effects that are worse than those they intended to treat in the first place (Padwal and 
Majumdar, 2007). Nutritional interventions for treating obesity should be considered. One simple 
method of treating obesity is through weight loss. Weight loss is associated with significant 
health and economic benefits (Ofei, 2005). This is most often done through dietary restriction to 
create a net caloric deficit. 
The Standard American Diet (SAD), also known as a Western Diet, is made up of a high 
carbohydrate intake, that includes processed sugars and refined carbohydrates. The prevalence of 
obesity has increased with carbohydrate intake (Figure 5). Studies done on high carbohydrate 
intake have been associated with higher risk of diabetes in obese patients (Sakurai et al. 2016). 
High carbohydrate and sugar intake have also been linked to high blood pressure, adipose tissue, 
insulin resistance, LDL cholesterol, and fasting blood triglycerides (Mirmiran et al. 2016). Sugar 
intake is the most dangerous source of dietary carbohydrates and thus contributor to obesity. 
Excess sugar consumption promotes the development of cardiovascular diseases (CVD) and type 
2 diabetes (T2DM). High fructose corn syrup (HFCS) found in sugary beverages is a harmful 
sugar and its metabolism leads to fatty liver, dyslipidemia, reduced insulin sensitivity, and an 
increase in uric acid levels (Rippe and Angelopolous, 2013, Melanson et al. 2007). 
Epidemiological data suggests that these direct effects of sugar are independent of body weight 
gain, which presents a two-fold risk for obese patients (Stanhope, 2016). The risk from adipose 
tissue to CVD and T2DM combined with further added risk from sugar in the diet.  
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Figure 5: Obesity prevalence and increased carbohydrate intake from 1960 to 2000. 
Adapted from Gross et al. 2004. The American Journal of Clinical Nutrition. 
 
1.2.2 – Obesity & Breast Cancer: 
 
The obesity epidemic has resulted in an increase of morbidity and mortality and the 
association of cancer and age-related diseases are increased with obesity. Obesity has been 
linked strongly to colon, female breast (postmenopausal), endometrium, kidney (renal cell), and 
esophagus (adenocarcinoma) cancers. With the high amount of refined sugar in the average diet, 
it is important to know that cancer cells show an increase in glucose uptake, higher rates of 
glycolysis, and an increased level of lactate secretion even in the presence of oxygen. This 
phenomenon is known as the Warburg effect (Warburg et al. 1927). An increase in glycolytic 
flux in cancer cells is associated with activated oncogenes and mutant tumour suppressors 
(Hanahan and Weinberg, 2011).  Data has suggested that overeating may be the most avoidable 
risk to cancer in non-smokers (Calle and Thun, 2004) with weight gain and obesity accounting 
for roughly 20% of all cancer cases (Wolin et al., 2010). Work done previously by Doll and Peto 
suggested that simply over nutrition from diet (causing overweight) accounted for 35% of all 
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cancer. More recent work done by the Center or Disease Control and Prevention showed that 
obesity and overweight accounted for over 40% of all cancers diagnosed in the United States in 
2014. More importantly, a staggering 55 percent of all cancers diagnosed in women are 
associated with overweight and obesity (CDC, 2016).  
In women, breast cancer is the most commonly diagnosed cancer, representing 25% of all 
cancer types, leading it to become the fifth most common cause of death in women (Rausch et al. 
2017). Obesity and weight gain are considered risk factors for postmenopausal breast cancer in 
women. Research has shown that the environment of cancer cells can affect proliferation or 
tumour development. Leptin, estradiol, and high glucose, factors high in obese patients, have 
been shown to stimulate cell proliferation in MCF7 human breast cancer cells (La and 
Giammanco, 2001). Obesity is correlated with hormonal profiles that are likely to stimulate 
breast cancer growth (Chlebowski et al., 2002). Obesity also increases the risk of aggressive 
breast cancer regardless of menopausal status (Stephenson and Rose, 2003). Leptin is a hormone 
that is made by adipose cells. Work done in our lab (Theriau) has demonstrated that a decrease in 
the adiponectin:leptin ratio as a result of increases in visceral adipose induced cell cycle entry in 
MCF7 cells and repressed p27 expression (Theriau et al. 2016). Leptin is involved in regulating 
the energy balance of the body by regulating, and inhibiting hunger. In obese patients, leptin is 
elevated in the blood and the body becomes desensitized to the hormone. Studies done on 
ketogenic diets (KD) have shown significant decreases in leptin in as short as 8 weeks and have 
shown inverse relationships with hydroxybutyrate (Sumithran et al., 2013). Leptin has also been 
shown to be stimulated by factors present in overweight post-menopausal women, including 
insulin, IGF, and estradiol (Garofalo et al., 2006). Estradiol is the primary female hormone, some 
of which can be produced by adipose tissue. In post-menopausal women specifically, obesity is 
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related to levels of circulating estradiol which itself has been linked to breast cancer risk. Theriau 
et al. (2016) also demonstrated a correlation between circulating estradiol and obesity. By 
implementing the consumption of KD in obese women, the risk of breast cancer is reduced due 
to a subsequent decrease in adipocytes and thus circulating estradiol  (Key et al., 2003). Obesity 
interventions should be the first line of defence to reduce risk of breast cancer in women.  
 
1.2.3 – Insulin & Breast Cancer: 
 
The role of insulin in breast cancer is also being carefully studied. Insulin is an anabolic 
hormone that has signaling pathways in hepatic, adipose, and muscle tissues. While it is mainly 
involved in glucose metabolism, it has also shown proliferative effects on cancer cells. Fasting 
and post-prandial hyperinsulinemia is seen in obesity-induced insulin resistance as a 
compensation method (Orgen and Mittelman, 2013). Recent studies in animal and human models 
have shown that hyperinsulinemia, high levels of circulating IGF-1, and type 2 diabetes can 
increase breast cancer development and progression (Lann and LeRoith, 2008). Type 2 diabetes, 
which can arise from a diet high in carbohydrates, has been seen in up to 16% of breast cancer 
patients. Old age and obesity are two major risk factors for type 2 diabetes and are also 
associated with increased breast cancer risk (Wolf et al., 2005). A high carbohydrate diet is 
especially harmful for obese diabetic patients, with increases in level of blood glucose, insulin, 
and serum triglycerides in patients with insulin resistance following a large carbohydrate meal. A 
higher carb diet also raises triglyceride levels and reduces HDL-cholesterol while promoting 
insulin resistance (Zammit et al. 2001). Research done on post-menopausal women showed that 
high fasting insulin levels leading to insulin resistance was associated with a 2.4-fold risk of 
developing breast cancer (Gunter et al. 2009). Other research has demonstrated that there is a 
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27% increase in the risk of breast cancer in women with type 2 diabetes (Boyle et al. 2012). This 
suggests that hyperinsulinemia is an independent risk factor for breast cancer and is helpful in 
explaining the obesity-breast cancer relationship. Thus, a decrease in obesity and its associated 
morbidities remains as an option for decreased breast cancer risk. 
The insulin receptor has two tyrosine kinase isoforms: IR-A and IR-B. The IR-A isoform 
is expressed in cancer cells, which is involved in proliferation and cell survival signaling through 
the Ras-MAPK (mitogen-activated protein kinase) pathway (Belfiore and Malaguarnera, 2011). 
Studies done on blocked insulin signaling with hydrolyzed products (e.g. Indole-3-Carbinol) 
arrest breast cancer cell proliferation by decreasing expression of IGF1 receptor and IRS1 
(Marconett et al. 2012). Inhibition of these two receptors has been shown to decrease PI3K/Akt 
signaling, while suppressing MCF7 xenograft growth in mice (Fox et al. 2011). The importance 
of the PI3k pathway in cancer has been demonstrated through proliferation of breast cancer by 
insulin (Rose and Vona-Davis, 2012). These same effects were reversed by an Akt inhibitor. In 
the same study, diabetic levels of glucose in vitro led to an increase in Akt expression, 
proliferation rate, and migration activity of breast cancer cells (Tomas et al. 2012).  
 The interaction of a higher carbohydrate diet leads to excess glucose, and insulin 
resistance over time. It is clear that insulin/IGF/IRS play a large role in cancer growth and pose a 
large risk for obese patients. A lower carbohydrate diet would be one avenue of prevention.  
 
1.3 - The Ketogenic Diet: 
 
Low carbohydrate diets have been shown to reduce body weight, body mass index 
(BMI), abdominal circumference, systolic and diastolic blood pressure, and fasting blood 
triglycerides (Santos et al. 2012). They have also been shown to reduce fasting glucose, glycated 
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haemoglobin, plasma insulin, plasma C reactive protein, and increase high-density lipoprotein 
(Sartorius et al. 2016). Because dietary carbohydrates are positively associated with weight gain 
and obesity (Ma et al. 2005), this presents an opportunity for a low carbohydrate diet to reduce 
caloric intake and induce weight loss. Besides a basic reduction in calories consumed, the 
reduction in insulin concentrations would promote free fatty acid mobilisation from body fat 
storage (Krieger et al. 2006). The ketogenic diet is quite simple – cut out all refined 
carbohydrates, and increase dietary fat (Figure 5). 
 
Figure 6: Ketogenic diet food pyramid. Note removal of refined carbohydrates and foundation of 
meat and fat sources. 
 
1.3.1 - The Ketogenic Diet & Obesity: 
 
The ketogenic diet (KD) or a low-carb high-fat diet (LCHF) is a low carbohydrate, 
moderate protein, and high fat approach to eating (Figure 6). It is a natural way of eating that is 
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similar to how our ancestors ate, as carbohydrates were rare and opportunistic (Krilanovich, 
2007). The ketogenic diet triggers the breakdown of fat in the liver by decreasing glucose and 
ultimately producing ketone bodies. Ketone bodies are an efficient fuel source for the human 
brain, heart, and skeletal muscle (Mitchell et al. 1995). These are metabolic adaptations by the 
body that are made when the insulin response is reduced and glycogen stores are depleted in 
muscle and liver tissue (Dashti et al. 2004). 
Ketosis is the process of producing ketones from fat in the liver. Ketone production 
occurs after a few days of fasting, or when dietary changes are made from the form of diet and 
carbohydrate intake is reduced to roughly 20g per day (Felig et al. 1969). At this point the body 
does not have enough glucose reserves to produce oxaloacetate which supplies normal fat 
oxidation to the Krebs cycle. It also has an insufficient amount of glucose to supply the central 
nervous system (CNS) (Owen, 2005). In order to make up for the lack of energy supply, the body 
overproduces acetyl-CoA in order to produce three distinct ketone bodies (KB): acetoacetate 
(AcAc), β-hydroxybutyrate (HB), and acetone. The primary circulating ketone body is β-
hydroxybutyrate (βHB). The process of producing ketone bodies for fuel is called ketogenesis 
and it occurs in the mitochondrial matrix of the liver (Fukao et al. 2004). 
A reduction in caloric and fat intake combined with exercise has shown poor weight 
reduction long-term (Kramer et al. 1998). As previously mentioned, low-carb diets like the 
ketogenic diet are beneficial for reducing cardiovascular markers of heart disease in obese 
patients. They are also extremely effective at weight loss in obese patients (Dashti et al. 2003). 
Further studies done on obese diabetic patients (T2DM) showed a significant decrease in body 
weight, BMI, blood glucose, total cholesterol, LDL-cholesterol, triglycerides and urea from week 
1 to week 56. This was matched with a significant increase in HDL-cholesterol, with a higher 
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significance in patients with high blood glucose levels versus those with normal blood glucose 
levels (Dashti et al. 2007). Multiple research papers have shown similar results with 
improvements in cardiovascular markers and a reduction in body weight versus other diets 
(Dashti et al. 2003, Rabast et al. 1979, Dashti et al. 2004, Dashti et al. 2006, Yancy et al. 2004, 
Westman et al. 2003, Kwiterovich et al. 2003, Sharman et al. 2002, Lofgren et al. 2005, Boden et 
al. 2005, Ezenwaka and Kalloo, 2005).  
 
 
Figure 7: ATP production via ketones produced on a ketogenic diet 
 
The mechanism behind ketone production is responsible for many of the health benefits 
of a ketogenic diet. During fasting or ketosis in humans, ketones are is produced via dietary fat 
and endogenous adipose tissue. Free fatty acids are converted in the liver to ketone bodies which 
can provide energy to the mitochondria of cells. ATP is then produced by the conversion of 
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ketone bodies to acetyl CoA via the tricarboxylic acid cycle and oxidative phosphorylation 
(Figure 7). This allows protein sparing from lean tissue, while serving glucose-sparing effects as 
ketone bodies become the preferred energy substrate of the heart and muscle. To achieve a state 
of ketosis, it is typically recommended for males to consume below 30-50g of carbohydrates a 
day, and for women to consume below 20-30g of carbohydrates a day. The fat intake will 
represent 60-70% of calories, with protein combining for the remaining 30-40%, and 
carbohydrates around 5% (Westman et al. 2003). By tapping into adipose tissue, improving 
cardiovascular risk factors, and providing an effective method of weight loss, the ketogenic diet 
can directly and indirectly benefit obese patients. 
 
1.3.2 – Ketogenic Diet & Breast Cancer: 
 
The ketogenic diet could have implications for indirectly and directly slowing down 
cancer cell growth. Through the reduction in adipose tissue, the reduction of insulin, glucose 
(and other factors associated with cancer growth), along with the theory of mitochondrial 
dysfunction present in cancer cells. Mitochondrial dysfunction in cancer cells is thought to be 
one reason that ketone bodies can slow down cellular growth. Ketone bodies, mainly beta‐
hydroxybutyrate (β‐OHB), are converted back to acetyl-CoA inside the cell to eventually create 
energy. The expression of two key mitochondrial enzymes β‐OHB dehydrogenase (β‐OHBD) 
and succinyl‐CoA: 3‐ketoacid CoA transferase (SCOT) are responsible for this conversion 
(Chriett and Pirola, 2015). While ketone bodies are an efficient fuel source for regular human 
tissue, certain cancer cells show an impairment in their abilities to metabolize ketone bodies 
(Chia-Chi Hsu et al. 2016). 
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Early in 1927, Otto Warburg recognized that nearly all cancer calls share a common 
metabolic phenotype. They can be grouped together by their shift in metabolism from aerobic 
respiration towards glycolysis that is independent of oxygen availability, allowing them to 
survive in hypoxic conditions (Warburg et al. 1927). Typically, normal cells that have functional 
mitochondria can exercise their mitochondrial oxidative metabolism by shuttling pyruvate 
generated via glycolysis to the tricarboxylic acid (TCA) cycle. Unlike normal cells, cancer cells 
primarily use pyruvate in the lactic acid fermentation pathway (Branco Ana F. et al. 2016). This 
metabolic phenotype offers cancer cells three select advantages for survival. First, it is 
advantageous for proliferation as it allows more an efficient generation of carbon equivalents for 
macromolecular synthesis when compared with oxidative phosphorylation (OXPHOS) (Vander 
Heiden et al. 2009). Secondly, it prevents production of reactive oxygen species by bypassing 
mitochondrial oxidative metabolism. This is advantageous to cancer cells, as they have higher 
steady-state levels of oxidative stress relative to normal cells. This would improve survival as 
they would be more sensitive to ROS-mediated apoptotic stimuli (Aykin-Burns et al. 2009). 
Lastly, an increase in acidification of the tumour site, as a result of elevated glycolytic flux, can 
facilitate tumour invasion and progression (Peppicelli et al. 2014). 
There are a few factors that can contribute to the shift towards a glycolytic phenotype. 
Metabolic transformations that occur can be caused by mutations in genes coding for certain 
pathway proteins, or due to factors in the cellular microenvironment. Overactivation of 
insulin/IGF-1-dependent phosphatidylinositol 3‐kinase (PI3K)/Akt/mammalian target of the 
rapamycin (mTOR) system is one source of metabolic transformation (Baserga, 2000, 
DeBerardinis et al. 2008, Robey and Hay, 2009). Mutations in genes that code for proteins in 
pathways like PI3K-Akt are possible sources of metabolic transformation (Engelman, 2009). 
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Factors in the tumour microenvironment that are hallmarks of cancer, like hyperglycaemia and 
hyperinsulinemia, could also be sources of this shift in cellular metabolism (Klement and 
Kämmerer, 2011). Upregulation and membrane translocation of glucose transporters (GLUT) 
leads to an increase in glucose uptake and retention via activation of PI3K/Akt/mTOR pathway 
(Makinoshima et al. 2015). Downstream effectors of mTOR (c‐Myc and HIF‐1α) upregulate 
important glycolytic enzymes to reinforce glycolysis (Parajuli et al. 2015). Meanwhile, the 
downregulation of carnitine palmitoyl transferase 1A (CPT1A) via PI3K/Akt inhibits β‐
Oxidation (Schlaepfer, 2014). Uptake of glucose, along with increased glucose levels are 
associated with poor prognosis in cancer patients (Kunkel et al. 2003).  
These data further support the notion that the ketogenic diet, and the state of nutritional 
ketosis, should interfere with the dependence of cancer cells on glucose to grow, produce energy, 
and thus proliferate. The metabolism and genome of cancer cells allows for the potential to 
selectively starve them of glucose while providing energy via ketones to normal cells (Seyfried 
et al. 2011). Research has shown that non-hepatic tumours may be unable to metabolize ketone 
bodies (Tisdale and Brennan, 1983) and that gene expression for mitochondrial enzymes, beta-
hydroxybutyrate dehydrogenase and succinyl-CoA: 3-ketoacid CoA transferase was lower in 
tumours versus normal tissue (Zhou et al. 2007). Structural defects that lead to mitochondrial 
abnormalities in cancer cells are another source of inefficient ketone body metabolism (Seyfried 
et al. 2012). Another benefit of a ketogenic diet is that the reduction in circulating glucose will 
lower insulin and IGF-1 levels, resulting in a decrease of activation in the PI3K/Akt/mTOR 
pathway (Figure 8). By limiting or inhibiting insulin secretion there is an additional method that 
is consistent with published mechanisms to downregulate this pathway in patients with advanced 
cancer (Fine et al. 2012). 
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Figure 8: Reduction in glucose and insulin downregulates the PI3K/Akt/mTOR pathway. 
Tumours are unable to efficiently metabolize ketone bodies. 
Adapted from Branco et al. 2016. European Journal of Clinical Investigation. 
 
In vitro, there were inhibitory effect of ketone bodies (-hydroxybutyrate and 
acetoacetate) on tumour cell growth in breast cancer cell lines (Fine at al. 2009). Patients with 
breast cancer have shown positive results represented by a novel tumour marker, transketolase-
like-1 (TKTL1), associated with aerobic glycolysis of tumour cells (Jansen and Walach, 2016). 
Further studies are being done in clinical trials with patients suffering from breast cancer 
(NCT02092753). The ketogenic diet, through the depletion of glucose and the production of 
ketone bodies, warrants further research as an adjuvant to cancer therapy.  
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2.0 – Study Rationale: 
 
 There are clear effects of alterations in the tumour growth microenvironment that adipose 
in obese patients imparts on accelerating cancer proliferation (Theriau and Connor, 2017). Thus, 
reductions in adiposity by any means may serve to improve patient prognosis in obese patients. 
Ketogenic diet (KD) reduces adiposity as a secondary effect, but also increase ketones, decreases 
glucose, and decreases insulin directly. This thesis was designed to determine if these primary 
effects of KD can affect breast cancer growth and metabolism in the absence of the secondary 
effects of KD. Reductions in adiposity typically takes weeks, however KD-induced changes in 
glucose and insulin can occur within a matter of days. Thus, this thesis looks at primary and 
immediate effects seen in the tumor microenvironment.  
 
3.0 – Hypotheses: 
 
Based on the literature described in Section 1, I hypothesize that: 
1. The changes in ketones (HB), insulin and glucose that accompany KD will affect 
metabolism of MCF7 cells. 
2. In addition, the increase in ketones, decrease in glucose and decrease in insulin will 
promote an increase in p27. 
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4.0 – Manuscript:  
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4.1 – Abstract: 
 
Adipose tissue in lean cancer patients acts as an endocrine gland that secretes an 
adipokine profile which creates a tumour microenvironment that impairs tumour growth, while 
the profile secreted by obese adipose tissue promotes tumour growth. Dietary alteration is a 
powerful intervention to reduce body fatness, and one such alteration is the ketogenic diet (KD). 
In addition to a decrease in adiposity, KD decreases glucose and insulin while increasing ketone 
bodies. We set out to determine whether these individual alterations alone, or in concert, would 
affect MCF7 breast cancer cells, promoting cell cycle arrest. Experiments showed that 24 hour 
and 48 hour treatment with HB in a standard high glucose, high insulin conditions caused 
changes in the protein expression of pAktT308 and p27T198. In addition, HB treatment appeared 
to elicit a 2-fold increase in cytochrome c oxidase subunit IV (COX IV) protein levels. When 
glucose was decreased to post-prandial physiological glucose levels we saw HB dose-
dependent increases of COX IV and total p27 protein with a decline as HB approached the 
upper end of physiological HB levels (14mM). At the lowest glucose concentration there was 
an observed increase in AMPK phosphorylated at T172 and a decrease in both pAktS473 and 
pAktT308. Thus, the primary changes induced by a KD may themselves induce growth inhibitory 
effects on breast cancer cells. When combined with the established effects of decreasing 
adiposity on breast cancer proliferation, KD may change the tumour growth microenvironment 
in multiple ways to effectively slow tumour growth in breast cancer patients.  
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4.2 – Introduction: 
 
The ketogenic diet (KD) is a low carbohydrate, moderate protein and high fat diet that 
was initially used in the 1920s to treat epilepsy (Wilder and Winter, 1922). Since then, this diet 
has also been used in the treatment of pancreatic cancer, malignant brain cancer, Alzheimer’s 
disease, and traumatic brain injury (Gasior et al., 2006). During times of decreased carbohydrate 
availability, such fasting or prolonged exercise, ketone bodies are produced from body fat stores 
and circulated as an accessible source of energy. (R)-3-hydroxybutyrate (HB) is the most 
abundant and stable ketone body produced in humans (Newman and Virdin, 2014). It is a 
physiological alternative to glucose and fatty acids as an energy producing substrate via its 
conversion to Acetyl-CoA. During prolonged fasting, or controlled consumption of a KD, these 
ketone bodies rise to levels between 3-7mM in the blood. This is considered a safe and 
nutritional level of ketosis (Courchesne-Loyer et al. 2013). When glycogen stores in the liver and 
muscle are depleted, as occurs during the consumption of KD, fatty acids in the adipocytes are 
released in to the circulation. These fatty acids can subsequently be broken down and converted 
into ketone bodies in the liver, and then released into the systemic circulation. Metabolically 
active tissues like muscle and the brain are able to convert ketones into Acetyl-CoA, which 
enters the citric acid cycle in the mitochondrion and is converted into ATP in the presence of O2. 
Importantly, ketosis allows for glucose sparing by circumventing glycolysis (Berg et al., 2002). 
This shift in metabolism to ketone bodies as a fuel source increases high-density lipoprotein-
cholesterol, decreases fasting circulating levels of glucose, decreases low-density lipoprotein-
cholesterol and decreases triglycerides in the circulation (Paoli et al., 2013).  
During normal energy status in metabolically active tissue, most cellular energy is 
produced through the breakdown of glucose, via glycolysis, into pyruvate which is shuttled into 
    31 
the mitochondrion to produce ATP via oxidative respiration. In cancer cells this pattern is 
altered, whereby there is a much less reliance on aerobic means for energy production. This shift, 
termed the Warburg effect (Warburg et al., 1927), allows cancer cells to thrive in a hypoxic 
environment and represents one of the hallmarks of cancer (Hannahan and Weinberg, 2011). 
This leads to glycolytic breakdown of glucose in cancer cells with a reduced contribution of 
aerobic energy production through oxidative phosphorylation, giving cancer cells a growth 
advantage as they exist in hypoxic environments. Since KD decreases blood glucose, cancer cells 
may be starved of their primary fuel source in patients consuming a KD. While normal cells can 
use ketone bodies for aerobic respiration, cancer cells may struggle in this regard due to their 
inherent impairments in oxidative phosphorylation in the mitochondria, as evidenced when 
tumours in mice fed a KD decreased in size by 65% (Gluschnaider et al., 2014). 
Through the alterations in IGF, insulin, estradiol, and many of the over 400 hormones 
produced by adipose tissue, the metabolism of an obese person creates a tumour growth 
microenvironment that promotes cancer proliferation (Sartorius et al., 2016). One way to reverse 
this microenvironment in obese people may be by introducing a high fat, low carbohydrate diet 
instead. This induces nutritional ketosis which may affect breast cancer growth by decreasing 
adiposity (Veech, 2014). These effects of obesity can be reversed by altering the secretory 
function of adipose tissue via diet, exercise and nutritional supplementation (Connor and 
Theriau, 2013, Theriau et al. 2016, Theriau and Connor, 2017). Thus, KD may induce primary 
and secondary effects of KD consumption and highlight the possibility of implementing a KD as 
an adjuvant therapy in obese cancer patients.  
 
 
    32 
4.3 - Materials and Methods: 
 
Cell Culture 
MCF7 cells (ATCC, Manassas, VA) were cultured in flasks (T75 Falcon) at 37oC and 5% CO2, 
in alpha’s modification of eagle’s medium (AMEM; Sigma, St. Louis, Missouri), 5% fetal 
bovine serum (FBS; Wisent, St. Bruno, QC), 5% non-essential amino acids (Sigma), 5% sodium 
pyruvate (Sigma) 500l of insulin (10g/ml, Sigma), 3% antimycotic/antibiotic (Wisent) and 
media was replenished every 48 hours.  
Treatment 
Following trypsinization, MCF7 cells were seeded in 6-well plates. To test the effect of insulin 
on growth, cells were grown in varying levels of insulin (0−10g/ml). Manipulation of the dose 
of insulin in the growth media was done since circulating insulin levels decrease during KD 
consumption. MCF7 cells were plated at 80% confluence and starved of insulin for 24 hours in 
AMEM. Insulin was added back for 24 hours and cells were collected. To test the effects of 
ketone bodies, MCF7 cells were treated with -hydroxybutyrate (HB, 3.5-14mM), a range of 
ketone bodies found in the circulation during nutritional ketosis, for 24 and 48 hours. We also 
examined the effect of altering glucose levels (0-10mM). To assess the cumulative effects of 
insulin, glucose and HB, glucose-free AMEM (Sigma) was supplemented with 5g/ml of 
insulin and treated with various combinations of D-glucose (Sigma) and HB. Prior to 
HB/glucose treatment, a 6 hour glucose depletion time was implemented. Following depletion, 
glucose was added back to the media and cells were collected 18 hours later for a total treatment 
time of 24 hours.  
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Cell Harvesting 
Following all treatments, media was suctioned off, and cells were washed twice with cold 
phosphate buffered saline (PBS). Cells were then scraped, washed twice with cold PBS and the 
remaining pellet was resuspended in 0.2% TENT buffer solution (TRIS, EDTA, NaCl, 0.2% 
Triton x-100) supplemented with 1% protease inhibitor (Sigma, Oakville, ON), and 1% 
phosphatase inhibitor (Roche Diagnostics, Indianapolis, IN). The cells were then sonicated on 
ice and centrifuged at 16,100 xg at 4oC. The supernatant was then separated from the pellet and 
the protein lysate stored at -84oC. 
Immunoblotting 
Protein concentrations of experimental lysates were determined using a standard Bradford assay 
(Bio-Rad). To assess effects of treatments 25g of protein was loaded onto a 12% SDS-PAGE 
gel and run at 120V for 90-120 minutes. Separated proteins from the gel were then transferred 
onto a PVDF membrane (Bio-Rad, Mississauga, ON) overnight at 40V at 4oC. These membranes 
were stained in amido black the next day to determine the efficacy of transfer and blocked in 
10% skim milk with shaking at room temperature. Subsequently, membranes were incubated 
with primary antibodies overnight at 4oC for: Cyclin E, AMPK, pAMPKT172, Akt, pAktT308, 
pAktS473 (Cell Signaling, Pickering, ON), p27 (BD Biosciences, Mississauga, ON), p27T198 
(R&D Systems, Minneapolis, CA), Cox IV (Abcam, Cambridge, MA), AdipoR1 (Santa Cruz 
Biotech, Santa Cruz, CA) and β-Actin (Abcam, Cambridge, MA). Membranes were subsequently 
washed with Tris-Buffered Saline with 0.05% Tween (TBST) and then incubated with the 
appropriate HRP-linked secondary antibody (Cell Signaling) in 5% milk for 1 hour with shaking 
at room temperature. Proteins were visualized using an enhanced chemiluminescence substrate 
(Millipore, Whitby, ON) and imaged on a Kodak In Vivo FX Pro Imager (Marketlink Scientific, 
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Burlington, ON) and quantified using Carestream software. Protein loading was corrected to β- 
Actin levels. 
Statistical Analyses 
Statistical analyses were performed using GraphPad Prism 5 software. One-way ANOVAs were 
conducted to determine the effects of insulin, HB, and glucose. Differences in means were 
considered statistically significant when p0.05 and Tukey’s post-hoc test was performed to 
determine if there was any statistical significance between groups.  
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4.4 – Results: 
 
Insulin regulates pAkt pathway and can cause insulin resistance in MCF7 cells 
 Treatment of MCF7 cells without insulin resulted in low levels of phosphorylation of Akt 
on the T308 and S473 residue, while total Akt was unaffected. With a 5 g/ml dose of insulin, 
half of the standard amount supplemented in normal MCF7 growth media, we saw increases in 
pAktT308 and pAktS473 in protein expression, while total Akt was unaffected (Figure 9A). When 
insulin was further increased to 10 g/ml of insulin, there were observed reductions in pAktT308 
and pAktS473 protein levels (Figure 9B,C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9:  
Insulin dose in high glucose medium affects Akt activation in MCF7 cells. pAktT308 (A,B) and 
pAktS473 (A,C) saw significant increases in protein expression with a 5g/ml dose of insulin. 
This is roughly 5x physiological levels of post-prandial insulin.  All values are mean ± S.E.M.; * 
p<0.05 compared to control (n=6). 
A 
B C 
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HB affects mitochondrial protein expression 
 Treatment of ketone bodies caused a dose dependent increase in protein expression of 
COXIV. This protein is a marker of mitochondrial content, found in Complex IV of the electron 
transport chain. In both 24 hour (Figure 10A) and 48 hour (Figure 10B) treatments, we saw a 
step-wise increase in COX IV. 
 Total AMPK protein expression was unaffected in the 24 hour treatment (Figure 10A). 
However, Total AMPK protein expression was reduced by HB with significant differences 
observed between 0 and 5mM of HB in the 48 hour treatment (Figure 10B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: HB treatments in high glucose medium with 10g/ml of insulin lead to a step-wise 
increase in COX IV for 24 hour and 48 hour treatments and lowered total AMPK in the 48 hour 
time course (B). Significant decrease from 0-5mM of HB in total AMPK for 48 hour treatment. 
Increases in COX IV protein for 24 hour and 48 hour treatments of HB (0, 3.5, 5, 7, and 
14mM). All values are mean ± S.E.M.; * p<0.05 compared to control (n=4-8). 
A B 
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HB in high glucose medium does not affect p27 
Total p27 protein was unchanged in response to HB treatment in high glucose AMEM, 
with both a 24 hour and 48 hour treatment (Figure 11A,B). However, p27T198 was significantly 
reduced following a 48 hour treatment of HB (Figure 11B). While no changes were evident 
after a 24 hour treatment of HB exposure, after a 48 hour treatment of HB there was a 
reduction in p27T198 when expressed as a percentage of total p27 (Figure 11A,B). 
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Figure 11: 
HB treatment in high glucose medium with 10g/ml of insulin did not change p27 protein but 
destabilized the phosphorylated p27 on the T198 residue with 48 hour treatment (A,B). No 
changes occurred in total p27 protein expression between control and 3.5mM of HB for 24 hour 
and 48 hour treatments (B). Significant decrease was seen in p27T198 between control and 3.5, 5, 
and 7 mM in 48 hour treatments. Significant decrease was seen in p27T198 as a percentage of total 
p27 protein between control and 3.5, 5, and 7 mM in 48 hour treatments. All values are mean ± 
S.E.M.; * p<0.05 compared to control (n=4-8). 
A B 
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Ketone treatment downregulates the pAkt pathway 
 
No effects were seen after a 24 hour treatment of HB (Figure 12A) but increasing HB 
in the presence of high glucose AMEM at a 48 hour treatment decreased pAktT308 with 
significant decreases observed at 5mM HB. (Figure 12B). Similarly, protein expression of 
pAktT308 as a percentage of total Akt was significantly unchanged after 24 hour treatment (Figure 
12A) but was reduced from control to 5mM of HB in a 48 hour treatment condition (Figure 
12B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: 
HB treatment in high glucose medium with 10g/ml of insulin. pAktT308 protein expression saw 
significant changes in the 48 hour time course with total Akt staying fairly consistent across both 
time courses (B). pAktT308 decreased in a step-wise manner between control, 3.5mM and 5mM 
HB with 48 hour treatment. pAktT308 as a percentage of total Akt decreased in a step-wise 
manner between control, 3.5mM and 5mM HB with a 48 hour treatment. All values are mean ± 
S.E.M.; * p<0.05 compared to control (n=4-8). 
 
A B 
    40 
HB increases mitochondrial content and p27 
 
The shift from high glucose AMEM to a glucose controlled DMEM treatment media was 
intended to test the effects of decreasing glucose and ketones to physiological levels observed 
during nutritional ketosis. Treatment of HB with a range of physiological levels of glucose (0, 
1, 2, and 5mM) increased the protein expression of the mitochondrial marker COX IV and also 
increased expression of total p27 protein (Figure 13A-D). This consistently appears as a step-
wise increase with a decrease, seen at high levels of HB (14mM) (Figure 13A-D). At high 
levels of glucose (10mM) we don’t see changes in protein expression across HB treatments 
relative to control (3.5, 5, 7, and 14mM) (Figure 13E). Clearly, the biggest effects are seen at 
physiological levels of HB and glucose (1-2mM). As glucose climbs to 10mM, these effects are 
no longer evident (Figure 13A,E). 
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Figure 13: 
(A-D). HB treatment with 5g/ml insulin across glucose (mM) treatments 0, 1, 2, and 5 lead to 
dose-dependent increase in protein expression of p27 and COX IV (E). Plateau effects of HB 
treatment were seen in 10mM glucose for p27 and COX IV protein levels. All values are mean ± 
S.E.M.; * p<0.05 compared to control (n=6). 
 
A 
B 
C 
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AdipoR1 levels stay constant with HB treatment 
AdipoR1 protein expression was unchanged in treatments with HB independent of 
glucose levels (Figure 14A-B). No changes were seen with HB treatment across all glucose 
conditions (0, 1, 2, 5, 10mM) similar to the effects in 2mM glucose shown in Figure 14. 
AdipoR1 was not necessarily expected to change, but was examined because its protein 
expression is increased in breast cancer cells following weight loss and slows cancer growth. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: 
HB treatment with 5g/ml across all glucose (mM) treatments 0, 1, 2, 5, 10 lead to consistent 
AdipoR1 protein expression (B). AdipoR1 expression gradually increases at 5mM and 7mM 
HB treatments, however relatively unchanged across all experiments. All values are mean ± 
S.E.M.; * p<0.05 compared to control (n=6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
    43 
AMPK phosphorylation increases with HB treatment under low glucose conditions 
 
 Treatment of MCF7 cells with HB in a low glucose environment (1mM) lead to 
increased levels of pAMPKT172 in a dose-dependent manner with a potential decrease at 14mM 
(Figure 15B). When normalized to Total AMPK, pAMPKT172 increased  in a dose-dependent 
manner (Figure 15C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: HB treatment with 5g/ml insulin and 1mM glucose upregulated the pAMPK 
pathway (B). pAMPKT1728 is upregulated in a dose-dependent manner between 0, 3.5 and 5mM 
of HB, with a plateau between 5, 7 and 14mM of HB (C). pAMPKT172 as a percentage of total 
AMPK is upregulated in a dose-dependent manner between 0, 3.5, 5, 7, and 14mM of HB. All 
values are mean ± S.E.M.; * p<0.05 compared to control (n=6). 
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HB treatment under a low glucose condition decreases activation of the pAkt pathway 
 
The largest effects on pAkt were evident at 2mM glucose. pAktS473 was downregulated 
significantly between control and 5mM and 14mM of HB, with a similar downregulation when 
expressing pAktS473 as a percentage of total Akt (Figure 16B). Similarly, pAktT308 was 
downregulated significantly between control and 5mM of HB, with a similar downregulation 
when expressing pAktT308 as a percentage of total Akt (Figure 16C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: HB treatment with 5g/ml insulin and 2mM glucose downregulated the pAkt 
pathway (B). pAktS473 is downregulated in a dose-dependent manner between 0, 3.5 and 5mM of 
HB (C). pAktT308 is downregulated in a dose-dependent manner between 0, 3.5 and 5mM of 
HB. All values are mean ± S.E.M.; * p<0.05 compared to control (n=6). 
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4.5 – Discussion: 
 
 A reduction in obesity is known to decrease the growth of breast cancer (MCF7) cells. 
One way to decrease obesity is via a high fat, low carbohydrate ketogenic diet (KD). KD also 
increases the circulating levels of HB, which can be used as a fuel source in metabolically 
active tissues. We used a cell culture model to try to tease out the effects of the changing 
conditions that occur in the circulation following the implementation of a KD. Other established 
effects of KD include, but are not limited to, a reduction in insulin and glucose and an increase in 
ketone bodies produced by the mobilization/catabolism of FFA. Srivastava et al. showed that 
animals fed a KD significantly lowered blood glucose levels (<5mM) while -hydroxybutyrate 
(HB) levels increased compared to a chow fed group. Furthermore, insulin concentrations in the 
plasma for the KD group were about 60% lower than the chow group after a month of being on a 
ketogenic diet (Srivastava et al. 2012). Each of these changes represents an alteration in the 
tumour growth microenvironment. Thus, we evaluated the effects of each of these variable 
ranges across physiological ranges on MCF7 cell regulation. Our results suggest that 
physiological doses of ketone bodies (HB) are most effective at lower levels of glucose, which 
may be beneficial since KD is effective at reducing post-prandial glucose levels.  
Cytochrome c oxidase subunit 4 (COX IV) is one of 13 COX subunits and is often used 
as an indicator of cellular mitochondrial content. COX IV protein levels were upregulated in a 
dose dependent manner in response to increasing HB in both low and high glucose treatments. 
This increase in COX IV suggests that HB is directly leading to an increase in mitochondrial 
content, increasing the cell reliance on oxidative phosphorylation and possibly reversing the 
Warburg effect (Kogot-Levin et al. 2016). As the last enzyme of the mitochondrial respiratory 
chain, it is responsible for the catalytic transfer of electrons to molecular oxygen from reduced 
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cytochrome c. This reaction is paired with proton pumping across the inner mitochondrial 
membrane to establish an electrochemical gradient in the mitochondria (Calhoun et al, 1994). By 
removing glucose from treatment media, or adding HB, the metabolism of MCF7 cancer cells 
may have begun to shift from glycolysis towards oxidative phosphorylation in the mitochondria. 
MCF7 cells have impaired mitochondrial function and are sensitive to glycolytic inhibition 
(Pelicano et al. 2014). This increase in COX IV protein expression suggested that a decrease in 
glucose may act as a metabolic intervention to shift cancer cell metabolism that may make them 
less able to thrive in hypoxic conditions and confer a greater susceptibility to adjuvant therapies.  
AdipoR1 is affected by obesity-dependent changes in tumour growth microenvironment. 
Obese subjects typically show a decrease in circulating adiponectin and cellular AdipoR1 
receptor content, with a correlated increase in plasma leptin concentration (Ruhl and Everhart, 
2001). The binding of adiponectin to AdipoR1 typically upregulates AMPK, which plays a role 
in cellular metabolism and cell quiescence (Martha Daniela Mociño-Rodríguez et al. 2017). Our 
goal was to test AdipoR1 protein expression in order to see if HB induced any effects on 
AdipoR1 signaling and, as expected, AdipoR1 protein expression remained constant through all 
experimental conditions. Since we did not alter adipokines in our experiments, we hypothesized 
there would be no effect of HB on AdipoR1 protein levels. Despite increases in pAMPK, there 
were no changes in AdipoR1, suggesting primary effects of HB are independent of AdipoR1 
signaling (Figure 14).  
Insulin is an activator of the Akt pathway and promotes glucose uptake in fat and muscle 
tissue which are insulin-dependent (Ward and Thompson, 2012). HB treatment of MCF7 cells 
in a low glucose environment deactivated Akt signaling (pAktT308 and pAktS473; Figure 16A,B), 
potentially indicative of a reduction in reliance on glycolysis, as Akt activation is known to 
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increase glycolytic rates and lactate output in cells (Elstrom et al. 2004). This suggests that 
increases in HB, decreases in insulin and glucose, all of which occur following consumption of 
a KD, may render cells less reliant on glucose and anaerobic glycolysis as a means of energy 
production. In support of this, KD consumption in rats has been shown to downregulate mTOR, 
a downstream target of Akt (McDaniel et al. 2011). Akt is overexpressed in many breast cancers 
(Shi et al. 2005) and unfortunately Akt pharmaceutical inhibitors have shown little promise and 
are limited in their application due to their toxicity (Nitulescu et al. 2005). Given that KD 
consumption increases HB and decreases glucose, which we show decreases Akt activation, 
KD could play a role as an intervention for reducing breast cancer cell growth directly by 
naturally inhibiting Akt signaling. Fasting glucose levels are typically ≤ 2.5 mmol after 
ketogenic adaptation (Wiesli et al. 2012). Observations that at 2mmol glucose HB is most 
effective gives physiological and clinical relevance to our results (Figure 16B-C).  
In addition to decreasing Akt signaling, HB treatment at low glucose concentrations 
increased pAMPK signaling (Figure 15B). Based on previous work (Theriau et al. 2016), AMPK 
antagonizes Akt signaling and is beneficial in reducing MCF7 growth. This antagonization of 
Akt is also evident with HB treatment at low glucose concentrations. Previous work has 
demonstrated that KD increased AMPK expression (Kennedy et al. 2007) and AMPK 
phosphorylation in the liver (McDaniel et al. 2011) which agrees with the results herein. AMPK 
is widely acknowledged to be activated in calorie deficient conditions and inhibited when energy 
is in excess (Cantó and Auwerx, 2011). Ketosis should drive phosphorylation of AMPK when 
glucose and insulin are low in MCF7 cells (Klein and Wolfe, 1992, Horman et al. 2006). The 
increase in pAMPK at 1mM of glucose gives us further insight into the possibility that total 
energy available to MCF7 cells is potentially reduced under a ketogenic environment. 
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Increased AMPK in MCF7 cells has been shown to increase p27 and induce G1 arrest 
(Theriau and Connor, 2017). Treatment with physiological levels of HB indicated cell cycle 
arrest in some conditions due to the dose-dependent increase in total p27 protein when glucose 
levels are low (Figure 13B-D). HB did not affect p27 until glucose and insulin levels were low, 
conditions observed during KD consumption. p27kip1 is a powerful inhibitor of the cell cycle that 
is de-regulated in many types of cancer, including breast cancer (Slingerland and Pagano, 2000). 
p27 is also known to be increased during caloric restriction in tumours, further pointing to KD-
induced increases in HB being beneficial to creating an unfavourable growth environment for 
breast cancers (Zhu et al. 1999). The majority of studies looking at ketogenic diets and tumours 
show glucose levels between 3-10mM, with glucose levels dropping as ketone levels increased 
over time (Meidenbauer et al. 2005). This agrees with our results where we saw significant 
changes at 1, 2, and 5mM of glucose, levels that are the closest to physiological post-prandial 
glucose levels during KD consumption. It is important to note that all changes in protein 
expression were negated at glucose levels of 10mM. This level is considered a risk factor as a 
diabetic range of post-prandial glucose by the International Diabetes Federation suggesting that 
ketones alone are not effective as a counter measure to obesity dependent breast cancer 
risk/progression (5.6–11.0 mmol; Bowen et al. 2015). While changes in p27 appear 
physiologically significant, it still remains to be determined whether these changes lead to actual 
cell cycle arrest in response to HB when glucose and insulin levels are low. By limiting 
glucose, the preferred fuel source of breast cancer cells, and adding ketones we may be able to 
effectively reverse the Warburg effect, thereby eliminating one of the hallmark changes in cancer 
cells that allows for their survival in less than ideal (i.e. hypoxic) conditions. 
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Our results indicate that changes in the expression of proteins involved in metabolism 
and the cell cycle are affected by HB in low physiological glucose conditions. Our results also 
suggest that the implementation of a KD to increase ketones and reduce glucose and insulin 
would have similar effects on breast cancer cells in vivo. The Warburg effect is a hallmark of 
cancer that leads to a growth advantage for cancer cells and our results highlight the significance 
of ketone bodies in low glucose environments and the need for further research in the field of 
ketogenic diets on obesity and breast cancer. The importance of prevention in obese patients is 
highlighted by our experimental model, represented by the primary and secondary effects of KD 
in reducing glucose, insulin and adiposity. 
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5.0 - Overall Conclusions: 
 
The obesity epidemic has resulted in an increase of morbidity and mortality worldwide. 
In the United States alone, consumers annually spend more than $30 billion dollars on weight 
loss products and services (Serdula et al., 1999) along with $750 billion dollars on 
pharmaceuticals. Work done previously by Doll and Peto suggested that over nutrition from diet 
alone (causing overweight) accounted for 35% of all cancers (Doll and Peto, 1981). More 
recently, the Center for Disease Control and Prevention found that 55 percent of all cancers 
diagnosed in women are associated with overweight or obesity (CDC, 2016). My thesis aimed to 
show that the effects of KD, including reduced insulin and reduced glucose with an increase in 
circulating ketones, would force cancer cells to rely on a dysfunctional oxidative 
phosphorylation cycle for energy needs and potentially induce cell cycle arrest or death. 
Research suggests that ketone bodies may reduce tumour growth and altering ketones, insulin, 
and glucose levels within the tumour growth microenvironment may prove beneficial in cancer 
therapy.  
 It is becoming more evident that there are benefits to the ketogenic diet and that the co-
consumption of carbohydrates leading to higher levels of insulin may enhance signaling cascades 
to fuel tumour growth (Bonuccelli et al. 2010). Our experiments demonstrated that HB effects 
were most evident during low glucose conditions. It is realized that it is a tricky undertaking to 
recapitulate the effects of KD using a cell culture model given that the human body, organs, 
tissues, and surrounding hormones are incredibly complex. 
 My research was most importantly able to show increases in COX IV in response to HB 
treatment under low glucose conditions (Figure 13B-D). Cytochrome oxidase c is a protein that 
can be used as a marker for the OXPHOS (oxidative phosphorylation) system (Kogot-Levin et 
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al. 2016). Studies done on ketogenic diets have shown an increase in COX IV protein expression, 
along with markers of mitochondrial biogenesis (Srivastava et al. 2012). The increase in COX IV 
expression in our research was important because literature shows that some types of cancer have 
dysfunction in the mitochondria (Solaini et al. 2011). Another key finding is that ROS 
production from the OXPHOS system can cause cell cycle arrest and potentially slow down 
cancer cell growth by causing the cell to arrest during G1 (Yang et al. 2017).  
According to the Crabtree effect, there is a down-regulation of the catalytic subunit of the 
mitochondrial ATP synthase subunit, where expression level of β-F1-ATPase protein is inversely 
correlated with the rate of aerobic glycolysis (Diaz-Ruiz et al. 2011). One study done by the 
Fantin group showed that OXPHOS was enhanced when a glycolytic enzyme (LDH-A) was 
suppressed in cancer cells, in order to compensate for the reduction in ATP by glycolytic 
inhibition. Most importantly, they demonstrated that the shift to OXPHOS showed inhibition of 
proliferation and tumorigenicity of cancer cells which suggests impairment of OXPHOS to 
provide a sufficient amount of energy for cancer growth (Fantin et al. 2006). Based on the 
literature, stimulating ROS production in cells via glucose deprivation directly causes inhibition 
of cell proliferation (Aulwurm and Brand, 2000). Likewise, when glycolysis was enhanced, it 
reportedly protected cells from oxidative stress. Our findings of pushing MCF7 cells towards 
OXPHOS is also important due to the Warburg effect, where cancer cells typically show increase 
in glucose uptake and higher rates of glycolysis (Gogvadze et al. 2010). Our findings from the 
step-wise increase in COX IV and p27 protein under low glucose conditions, with a consequent 
decrease at toxic HB levels (14mM), further supports the notion that shutting off the glycolytic 
pathway and driving OXPHOS can promote cell cycle arrest at G1. 
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 p27kip1 is arguably one of the most important ‘brakes’ in the cell cycle. With its role in 
late G1/early S phase, it has been implicated in many studies done on cancer (Lloyd et al. 1999, 
Blain et al. 2003). A more recent study helps us tie the link between similar dose-dependent 
increase of COX IV and p27 protein expression in low glucose environments when treated with 
physiological levels of HB. Bachs et al. demonstrated that at least 18 genes that are involved in 
oxidative phosphorylation within the respiratory chain are downregulated in p27kip1 knock-out 
cells, which helps draw a bridge between the results that we observed (Bachs et al. 2018). Since 
p27 levels are low in breast cancer cells, we would expect to see a decrease in oxidative 
phosphorylation. The decrease in respiration leads to aerobic glycolysis and fuels tumour cells 
(Lunt and Heiden, 2011). Our results agree with the literature in that mitochondrial activity and 
p27 protein expression are upregulated in a similar manner (Figure 13B-D). This supports our 
hypothesis regarding the impairment of oxidative phosphorylation while activating markers of 
cell cycle arrest. Further research is needed to distinguish if they are related and if the effects 
seen on p27 are secondary.  
 Although our results did not show statistical significance likely due to variability and 
lower experimental numbers, we see a clear trend in our p27 protein expression. Based on the 
extensive literature done by the Lloyd group demonstrating that p27 expression decreases as 
tumours progress (Lloyd et al. 1999), this advanced our hypothesis that the reduction of glucose 
and the presence of ketone bodies promotes cell cycle arrest. Without FACS analysis, we are not 
able to clearly show cell cycle arrest during late G1. However, the pattern seen in p27 protein 
expression did provide some support to our hypothesis (Figure 13B-D). Diving deeper into 
MCF7 cells and breast cancer specifically, the literature in conjunction with the results we saw 
supports our hypothesis even further as p27 causes cell cycle arrest in G1 (Toyoshima and 
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Hunter, 1994). Further studies show that p27 expression is lower in more aggressive tumours 
(Catzavelos et al. 1997, Porter et al. 1997, Tan et al. 1997). The Tan group specifically found 
that decreased p27 in small invasive breast carcinomas were at a greater risk for tumour 
progression, and should consider an adjuvant therapy. The ketogenic diet in our case presents 
itself as an opportunity for a non-toxic, and non-invasive adjuvant to present cancer therapies to 
drive p27 expression in cancer cells and promote cell cycle arrest. 
 Activation of the Akt/PKB pathway, similar to p27, is a marker of poor health in breast 
cancer (Veeriah et al. 2014). Activation of the Akt/PKB protein kinase family is also known to 
trigger glycolytic activity (Mackenzie and Elliot, 2016). More recently, this family of proteins 
has emerged as the most frequently activated protein kinases in human cancer. Upon activation, 
Akt is able to phosphorylate downstream target proteins that are involved in glucose uptake and 
metabolism. It is extremely important to note that during prolonged fasting, which has similar 
effects on metabolism as a ketogenic diet, insulin levels approach zero. Mild ketosis can 
compensate for the metabolic effects of insulin in its absence (Veech, 2004). Thus, we could 
have a therapeutic approach to downregulating the Akt/PKB pathway without losing critical 
metabolic effects that insulin is responsible for.  
Our research on ketone treatment in both low and high glucose conditions showed a 
downregulation in Akt pathway activation. Our studies on the doses of glucose were done with 
treatment media supplemented at 5mg/ml of insulin, where we saw the highest protein 
expression of both pAktT308 and pAktS473 in our initial insulin experiments. Insulin comes into 
play when we consider that IGF-1 drives Akt phosphorylation to promote the cell cycle and fuel 
tumour growth (Chin and Toker, 2009). We were able to see significant decreases between 
control and 5mM of HB treatment in our low glucose condition, thus supporting the hypothesis 
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that the reduction of insulin and the presence of ketone bodies in a ketogenic diet will drive 
markers of cell cycle arrest. 
The KD produces ketone bodies as an alternative fuel source in the absence of glucose. 
This is the principle behind driving OXPHOS and attempting to reverse the Warburg effect. In 
order to slow down cancer growth, the brakes of the cell cycle (p27, AMPK) need to be activated 
while the gas pedals of the cell cycle need to be downregulated (Akt, glycolysis). The Akt 
downregulation and concurrent AMPK upregulation during low glucose conditions agrees with 
our working model (Figure 17B). AMPK also upregulates mitochondrial content, as evidenced 
by COX IV, through activation of PGC-1 The dose-dependent increases of p27 and COX IV at 
low glucose conditions further support this model. We begin to see a system where low glucose 
conditions and the production of HB via KD will lower insulin and repress glycolysis and 
proliferation through a complex interaction between Akt, AMPK, COX IV, and p27 (Figure 
17A,B). Based on the literature provided and changes in protein expression seen in our research, 
we were able to gain more insight into the topic of diet and cancer. The data suggested that 
mitochondrial dysfunction could occur in cancer cells and coincide with markers of cell cycle 
arrest. Thus, our results warrant further research on ketogenic diets as an intervention for obesity 
and breast cancer.  
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Figure 17: Current working model based on data and observations collected. Ketone body 
treatment in a low glucose and low insulin environment promotes a marker of cell cycle arrest 
and increases mitochondrial content in MCF7 breast cancer cells.  
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6.0 Limitations and Future Directions: 
 
6.1 Limitations: 
 
 As with all experimental models, our research model poses a few limitations to consider. 
The most important limitation is on the complexity of the human body and the cancer 
microenvironment. With a cell culture model, there is an oversimplification of the interactions 
between cancer cells and the pool of media present (tumour microenvironment). While work is 
being done in animal models on ketogenic diets and cancer, it is very rare in the scientific field to 
study this in-vitro, which allows us to control for variables like glucose and HB to study dose-
dependent relationships. This is an important research area that should be looked at further, but 
can be oversimplified when adapting the results to a human body.  
 Another potential limitation is the dose of insulin used in the treatment media. When we 
reduced insulin closer to physiological levels, we shut off the Akt pathway and struggled to 
capture protein expression during immunoblotting. The insulin levels used provided enough 
protein for imaging, however they were five-fold physiological levels at 5g/ml and could have 
masked changes in protein expression that would be induced by a low-glucose and high-ketone 
environment. It was also difficult to control for contributions of insulin and glucose from Fetal 
Bovine Serum (FBS) added to the growth media. However, contributions from FBS were likely 
limited, and the content was not drastically different from batch to batch. 
 Lastly, the treatment time was 24 hours and may be shorter than what is needed to see 
changes in protein expression. The ketogenic adaptation stage can take 2-3 days in humans, and 
has not been solidified in cell culture. The changes we were looking for in specific proteins may 
have not occurred we collected and analyzed lysates, or there may not have been enough time for 
enzymatic adaptations to take place, evidenced by 48 hour treatments showing increased effects. 
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6.2 - Future Directions: 
 
 This field of study is fairly new and is beginning to gain recognition over the past few 
years. Our research was able to look at the ketogenic diet (KD) as an intervention for obesity and 
breast cancer on a superficial level.  
6.2.1: Insulin 
 
 Future work in-vitro should take into consideration the importance of insulin levels and 
the role they play in the cell cycle. Arguably the most important component of this field of 
research, the next step would be to isolate the most physiological glucose and ketone level as the 
dependent variable, and test a dose-dependent treatment of physiological insulin as the 
independent variable. This would be a more accurate cell culture model to test the effects of a 
higher carbohydrate diet versus a ketogenic diet on breast cancer growth.  
6.2.2: Treatment Time 
 
 Work done on KD and cancer should consider a time-course treatment protocol. We 
know that ketogenic diets can reduce fasting insulin levels after just a few days. It would be 
interesting to see a time course less than, and greater than our treatment protocol using a defined 
set of variables. The same variables can be used for a 3, 5, and 7-day protocol to assess both 
short and long-term changes in protein expression.  
6.2.3: Animal Model 
 
 The most important literature in the field of ketogenic diets and cancer has been done in 
human and animal models. Xenograft models offer an advantage to studying tumour growth in 
response to a KD.  
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